Efficacy of methotrexate in ankylosing spondylitis: A randomized, double blind, placebo controlled trial

Journal of Rheumatology

Volumn 31, Issue 8, 2004, Pages 1568-1574

  Gonzalez Lopez, Laura ^a,d   Garcia Gonzalez, Araceli ^b   Vazquez Del Mercado, Monica ^c   Muñoz Valle, Jose F ^c   Gamez Nava, Jorge I ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Sect Musculoskel Dis/Autoimmunity   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d NONE   (Mexico)

Author keywords

Ankylosing spondylitis; Methotrexate; Randomized controlled trial

Indexed keywords

ANALGESIC AGENT; DICLOFENAC; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE FOR SPONDYLOARTHROPATHIES; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; THROMBOCYTOPENIA; VOMITING; WELLBEING;

EID: 3442880132     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Khan MA. Ankylosing spondylitis: clinical aspects. In: Calin A, Taurog JD, editors. The spondylarthritides. Oxford: Oxford University Press; 1998:27-40.
2. Bosi Ferraz M, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
3. Clegg DO, Red DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999;42:2325-9.
4. Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
5. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002;346:1349-56.
6. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.
7. Ferraz MB, da Silva HC, Atra E. Low dose methotrexate with leucovorin rescue in ankylosing spondylitis. J Rheumatol 1991;18:146-7.
8. Yamane K, Saito C, Natsuda H, et al. Ankylosing spondylitis successfully treated with methotrexate. Intern Med 1993;32:53-6.
9. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000;29:160-2.
10. Creemers MCW, Franssen MJAM, van de Putte LBA, Gribnau FWJ, van Riel PLCM. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995;22:1104-7.
11. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000;19:114-7.
12. Altan L, Bingöl U, Karakoc Y, Aydiner S, Yurtkuran M, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
13. Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moors RJ. Is methotrexate effective in ankylosing spondylitis? Rheumatology 2002;41:1330-2.
14. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
15. Garret S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
16. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
17. Van der Heijde D, Calin A, Dougados M, Khan MA, Van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. J Rheumatol 1999;26:951-4.
18. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
19. Daltroy LH, Larson MG, Roberts WN, Liang MA. Modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990;17:946-50.
20. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence. 2nd ed. London: BMJ Books; 2000.
21. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - Results from the German rheumatological database. J Rheumatol 2000;27:613-22.
22. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
23. Van der Heijde D, Braun J, McGonagle D, Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis 2002;61:24-32.